Coenzyme Q10 supplementation and heart failure

Nutr Rev. 2007 Jun;65(6 Pt 1):286-93. doi: 10.1301/nr.2007.jun.286-293.

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the Western world. Oxidative stress appears to play a pivotal role in atherosclerosis. Coenzyme Q10 (CoQ10), one of the most important antioxidants, is synthesized de novo by every cell in the body. Its biosynthesis decreases with age and its deficit in tissues is associated with degenerative changes of aging, thus implicating a possible therapeutic role of CoQl0 in human diseases. There is evidence to support the therapeutic value of CoQ10 as an adjunct to standard medical therapy in congestive heart failure. However, much further research is required, especially in the use of state-of-the-art techniques to assess functional outcomes in patients with congestive heart failure.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Aging / physiology
  • Antioxidants / physiology*
  • Antioxidants / therapeutic use
  • Cardiac Output, Low / drug therapy*
  • Coenzymes / physiology
  • Coenzymes / therapeutic use
  • Drug Interactions
  • Heart Failure / prevention & control*
  • Humans
  • Oxidative Stress / drug effects
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / physiology
  • Ubiquinone / therapeutic use
  • Vitamins / physiology*
  • Vitamins / therapeutic use

Substances

  • Antioxidants
  • Coenzymes
  • Vitamins
  • Ubiquinone
  • coenzyme Q10